bicalutamide has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fasoulaki, V; Giatromanolaki, A; Kakouratos, C; Kalamida, D; Koukourakis, MI; Mitrakas, A; Papadopoulou, E; Pouliliou, S; Xanthopoulou, E | 1 |
| Bayley, A; Bristow, R; Catton, C; Chung, P; Gospodarowicz, M; Hill, R; Menard, C; Milosevic, M; Panzarella, T; Parker, C; Toi, A; Warde, P | 1 |
2 other study(ies) available for bicalutamide and Hypoxia
| Article | Year |
|---|---|
Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Topics: Androgen Antagonists; Anilides; Autophagy; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Thiohydantoins; Tosyl Compounds | 2018 |
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.
Topics: Aged; Aged, 80 and over; Androgens; Anilides; Disease Progression; Humans; Hypoxia; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Oxygen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome | 2007 |